@article{16089,
  author = {Grobbee D. and van der Schouw Y. and van Dieren S. and Kengne Andre and Woodward Mark and Zoungas Sophia and Beulens J. and Poulter N. and Harrap S. and Mancia G. and Cooper M. and Chalmers J. and Neal Bruce and Patel Anushka},
  title = {Effects of blood pressure lowering on cardiovascular outcomes in different cardiovascular risk groups among participants with type 2 diabetes},
  abstract = {<p>
AIMS: To asses differences in treatment effects of a fixed combination of perindopril-indapamide on major clinical outcomes in patients with type 2 diabetes across subgroups of cardiovascular risk. METHODS: 11,140 participants with type 2 diabetes, from the ADVANCE trial, were randomized to perindopril-indapamide or matching placebo. The Framingham equation was used to calculate 5-year CVD risk and to divide participants into two risk groups, moderate-high risk (&lt;25% and no history of macrovascular disease), very high risk (&gt;25% and/or history of macrovascular disease). Endpoints were macrovascular and microvascular events. RESULTS: The mean age of participants was 66 years (42.5% female). 1000 macrovascular and 916 microvascular events were recorded over follow-up of 4.3 years. Relative treatment effects were similar across risk groups, (all P-values for heterogeneity &gt;/=0.38). Hazard ratios for combined macro- and microvascular events were 0.89 (0.77-1.03) for the moderate-high risk and 0.92 (0.81-1.03) for the very high risk. Absolute treatment effects tended to be greater in the high risk groups although differences were not statistically significant (P&gt;0.05). CONCLUSIONS: Relative effects of blood pressure lowering with perindopril-indapamide on cardiovascular outcomes were similar across risk groups whilst absolute effects trended to be greater in the high risk group.
</p>
},
  year = {2012},
  journal = {Diabetes Research and Clinical Practice},
  edition = {2012/06/09},
  month = {-35821081564},
  isbn = {1872-8227 (Electronic)0168-8227 (Linking)},
  note = {Diabetes research and clinical practiceDiabetes Res Clin Pract. 2012 Jun 5.Impact Factor 2.7},
  language = {Eng},
}